These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9638867)

  • 1. Effect of isoleucine on toxin production by Clostridium difficile in a defined medium.
    Ikeda D; Karasawa T; Yamakawa K; Tanaka R; Namiki M; Nakamura S
    Zentralbl Bakteriol; 1998 May; 287(4):375-86. PubMed ID: 9638867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxin production by Clostridium difficile in a defined medium with limited amino acids.
    Yamakawa K; Kamiya S; Meng XQ; Karasawa T; Nakamura S
    J Med Microbiol; 1994 Nov; 41(5):319-23. PubMed ID: 7966203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Clostridium difficile toxin production in biotin-limited conditions.
    Yamakawa K; Karasawa T; Ikoma S; Nakamura S
    J Med Microbiol; 1996 Feb; 44(2):111-4. PubMed ID: 8642571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of enhanced toxin production by Clostridium difficile in biotin-limited conditions.
    Yamakawa K; Karasawa T; Ohta T; Hayashi H; Nakamura S
    J Med Microbiol; 1998 Sep; 47(9):767-71. PubMed ID: 9736158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids.
    Karlsson S; Burman LG; Åkerlund T
    Microbiology (Reading); 1999 Jul; 145 ( Pt 7)():1683-1693. PubMed ID: 10439407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxin production of Clostridium difficile in sub-MIC of vancomycin and clindamycin alone and in combination with ceftazidime.
    Zarandi ER; Mansouri S; Nakhaee N; Sarafzadeh F; Moradi M
    Microb Pathog; 2017 Jun; 107():249-253. PubMed ID: 28286152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxin A-negative, toxin B-positive Clostridium difficile.
    Drudy D; Fanning S; Kyne L
    Int J Infect Dis; 2007 Jan; 11(1):5-10. PubMed ID: 16857405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth of Clostridium difficile and production of toxins A and B in complex and defined media.
    Haslam SC; Ketley JM; Mitchell TJ; Stephen J; Burdon DW; Candy DC
    J Med Microbiol; 1986 Jun; 21(4):293-7. PubMed ID: 3088279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-resolved amino acid uptake of Clostridium difficile 630Δerm and concomitant fermentation product and toxin formation.
    Neumann-Schaal M; Hofmann JD; Will SE; Schomburg D
    BMC Microbiol; 2015 Dec; 15():281. PubMed ID: 26680234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of arginine on toxin production by Clostridium difficile in defined medium.
    Karasawa T; Maegawa T; Nojiri T; Yamakawa K; Nakamura S
    Microbiol Immunol; 1997; 41(8):581-5. PubMed ID: 9310936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteins released during high toxin production in Clostridium difficile.
    Mukherjee K; Karlsson S; Burman LG; Åkerlund T
    Microbiology (Reading); 2002 Jul; 148(Pt 7):2245-2253. PubMed ID: 12101311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
    Endres BT; Bassères E; Khaleduzzaman M; Alam MJ; Chesnel L; Garey KW
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3519-23. PubMed ID: 27021314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of Clostridium difficile strains by polymerase chain reaction with toxin A- and B-specific primers.
    Wren BW; Heard SR; al-Saleh AI; Tabaqchali S
    J Med Microbiol; 1993 Feb; 38(2):109-13. PubMed ID: 8429535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A defined growth medium for Clostridium difficile.
    Karasawa T; Ikoma S; Yamakawa K; Nakamura S
    Microbiology (Reading); 1995 Feb; 141 ( Pt 2)():371-5. PubMed ID: 7704267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin inhibits toxin production in Clostridium difficile.
    Babakhani F; Bouillaut L; Sears P; Sims C; Gomez A; Sonenshein AL
    J Antimicrob Chemother; 2013 Mar; 68(3):515-22. PubMed ID: 23208832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linkage between toxin production and purine biosynthesis in Clostridium difficile.
    Maegawa T; Karasawa T; Ohta T; Wang X; Kato H; Hayashi H; Nakamura S
    J Med Microbiol; 2002 Jan; 51(1):34-41. PubMed ID: 11800470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to detect Clostridium difficile variant strains in a routine laboratory.
    Rupnik M
    Clin Microbiol Infect; 2001 Aug; 7(8):417-20. PubMed ID: 11591204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.
    Warny M; Pepin J; Fang A; Killgore G; Thompson A; Brazier J; Frost E; McDonald LC
    Lancet; 2005 Sep 24-30; 366(9491):1079-84. PubMed ID: 16182895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clostridium difficile strains not producing Toxin A, but producing Toxin B [toxA(-)tox B(+)]--etiologic agent of antibiotic associated diarrhoea (AAD) in Poland].
    Pituch H; Obuch-Woszczatyński P; Meisel-Mikołajczyk F; Łuczak M
    Med Dosw Mikrobiol; 2002; 54(1):45-53. PubMed ID: 12185683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxins, butyric acid, and other short-chain fatty acids are coordinately expressed and down-regulated by cysteine in Clostridium difficile.
    Karlsson S; Lindberg A; Norin E; Burman LG; Akerlund T
    Infect Immun; 2000 Oct; 68(10):5881-8. PubMed ID: 10992498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.